Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12224689 | 1.00 | TSHR (0.39) | TSHRCYP3A4CA2HSD17B10MEN1 | |
| SCHEMBL16546825 | 1.00 | TSHR (0.39) | TSHRCYP3A4CA2HSD17B10MEN1 | |
| SCHEMBL13566394 | 1.00 | TSHR (0.39) | TSHRCYP3A4CA2HSD17B10MEN1 | |
| SCHEMBL12508099 | 1.00 | TSHR (0.39) | TSHRCYP3A4CA2HSD17B10MEN1 | |
| SCHEMBL274348 | 1.00 | TSHR (0.39) | TSHRCYP3A4CA2HSD17B10MEN1 | |
| SCHEMBL12082008 | 1.00 | TSHR (0.39) | TSHRCYP3A4CA2HSD17B10MEN1 | |
| SCHEMBL17021464 | 1.00 | TSHR (0.39) | TSHRCYP3A4CA2HSD17B10MEN1 | |
| SCHEMBL16546834 | 1.00 | TSHR (0.39) | TSHRCYP3A4CA2HSD17B10MEN1 | |
| SCHEMBL3425470 | 1.00 | TSHR (0.39) | TSHRCYP3A4CA2HSD17B10MEN1 | |
| SCHEMBL11969800 | 1.00 | TSHR (0.39) | TSHRCYP3A4CA2HSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12597635-B2 | Electrochemical device | MURATA MANUFACTURING CO., LTD. (JP) | 2026-04-07 | — | — | US | disclosed |
| US-12095081-B2 | Electrolytic solution and electrochemical device | MURATA MANUFACTURING CO., LTD. (JP) | 2024-09-17 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20240014378-A1 | POSITIVE ELECTRODE AND ELECTROCHEMICAL DEVICE | MURATA MANUFACTURING CO., LTD. (JP) | 2024-01-11 | — | — | US | disclosed |
| EP-3689868-B1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS INC (US) | 2023-09-27 | — | — | EP | disclosed |
| US-20230223525-A1 | ELECTROCHEMICAL DEVICE | MURATA MANUFACTURING CO., LTD. (JP) | 2023-07-13 | — | — | US | disclosed |
| WO-2023274395-A1 | NUCLEIC ACID LIGAND AND CONJUGATE THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海拓界生物医药科技有限公司 | 2023-01-05 | — | — | WO | disclosed |
| WO-2022209595-A1 | POSITIVE ELECTRODE AND ELECTROCHEMICAL DEVICE | 株式会社村田製作所 | 2022-10-06 | — | — | WO | disclosed |
| EP-3832772-A1 | ELECTROLYTIC SOLUTION AND ELECTROCHEMICAL DEVICE | Murata Manufacturing Co., Ltd. (JP) | 2021-06-09 | — | — | EP | disclosed |
| US-20210151803-A1 | ELECTROLYTIC SOLUTION AND ELECTROCHEMICAL DEVICE | MURATA MANUFACTURING CO., LTD. (JP) | 2021-05-20 | — | — | US | disclosed |
| WO-2021020265-A1 | COLORED CURABLE RESIN COMPOSITION | 住友化学株式会社 | 2021-02-04 | — | — | WO | disclosed |
| WO-2016094509-A1 | BCL XL INHIBITORY COMPOUNDS HAVING LOW CELL PERMEABILITY AND ANTIBODY DRUG CONJUGATES INCLUDING THE SAME | ABBVIE INC. (US) | 2016-06-16 | — | — | WO | disclosed |
| EP-2029554-B1 | PYRAZINE DERIVATIVES AND USES THEREOF IN RENAL MONITORING | MEDIBEACON LLC (US) | 2014-03-19 | — | — | EP | disclosed |
| US-20130251637-A9 | FLUORESCENT COMPOUNDS | DYOMICS GMBH (DE) | 2013-09-26 | — | — | US | disclosed |
| EP-2495797-A1 | NONAQUEOUS ELECTROLYTE SOLUTION FOR SECONDARY BATTERY, AND SECONDARY BATTERY | Asahi Glass Company, Limited (JP) | 2012-09-05 | — | — | EP | disclosed |
| US-20120214073-A1 | NON-AQUEOUS ELECTROLYTE SOLUTION FOR SECONDARY BATTERIES, AND SECONDARY BATTERY | ASAHI GLASS COMPANY, LIMITED (JP) | 2012-08-23 | — | — | US | disclosed |
| US-20110218156-A1 | MOLECULAR ENTITIES FOR BINDING, STABILIZATION AND CELLULAR DELIVERY OF NEGATIVELY CHARGED MOLECULES | RGO BIOSCIENCE, LLC | 2011-09-08 | — | — | US | disclosed |
| US-7572356-B2 | Comprising electrode with film disposed on electrode surface, film including a redox enzyme and a hydrophilic redox polymer, and dialysis membrane disposed on film, wherein dialysis membrane serves to entrap redox enzyme and hydrophilic redox polymer in vicinity of electrode; leaching prevention | LIFESCAN SCOTLAND LIMITED (GB) | 2009-08-11 | — | — | US | disclosed |
| EP-1630234-B1 | Electrochemical-based sensor with a redox polymer and redox enzyme entrapped by a dialysis membrane | LIFESCAN INC (US) | 2008-12-10 | — | — | EP | disclosed |
| US-4146736-A | INSERTION OF OXYALKYLENE GROUPS INTO CHAIN-TYPE ETHERS, LEWIS ACID CATALYSTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | TSHR 4013/4885CYP3A4 4692/4885CA2 3150/4885 |
| US-20110218156-A1 | MOLECULAR ENTITIES FOR BINDING, STABILIZATION AND CELLULAR DELIVERY OF NEGATIVELY CHARGED MOLECULES | ANXA6, NR1H4, SLC10A1 | TSHR 2470/4885CYP3A4 4865/4885CA2 1467/4885 |
| US-12597635-B2 | Electrochemical device | CLCN2, HCN4, SLC26A3 | TSHR 1300/4885CYP3A4 2013/4885CA2 62/4885 |
| US-20130251637-A9 | FLUORESCENT COMPOUNDS | NCL, FUS, EFTUD2 | TSHR 3923/4885CYP3A4 3716/4885CA2 4187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.